Presented by cshlpress…

• It’s over! The big news of the day was GSK and Synta Pharmaceuticals (SNTA). GSK scrapped its development deal with Synta four months after the company suspended its Phase 3 SYMMETRY trial evaluating Elesclomol in patients with metastatic melanoma. An Independent Data Monitoring Committee found a higher rate of death in patients on Elesclomol vs. those in the control arm. Today, GSK walked… [BizJournals]

• The Guardian says Merck’s aleglitazar is big gamble. [The Guardian]

• Valeant Pharmaceuticals has found a new use for its topical 5-FU drug, Efudex: wrinkle remover! [Bloomberg]

• The FDA said children shouldn’t stop taking drugs that treat ADHD despite a study showing the stimulants may be associated with sudden death. [WSJ]

• FDA: Just a little bit more time for BioDelivery Sciences’ (BDSI) Onsolis. [Pharmalive]

• ADVENTRX Pharmaceuticals raises $2M. [BioSpace]

• Transdel Pharmaceuticals is ready to report top-line results from its Phase 3 study of Ketotransdel in 3Q09. [ClinicaSpace]

• Aegerion Pharmaceuticals Lomitapide (AEGR-733) is about to give Isis Pharmaceuticals’ (ISIS) mipomersen a run for its money. [BusinessWire]

• Jazz Pharmaceutical (JAZZ) shares continue to skyrocket on positive fibromyalgia data. [Reuters]

• Finally, Novo Nordisk says the batch of insulin that was reported stolen over the weekend has been found! [MSNBC]

Anonymous Tip? Comments? Contact us: hr AT iguanabio DOT com

Related Posts